Radiation therapy to the primary in metastatic prostate cancer

Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013

Mickisch, 2001, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet Lond Engl, 358, 966, 10.1016/S0140-6736(01)06103-7

Cortet, 2013, Patterns of recurrence of obstructing colon cancers after surgery for cure: a population-based study, Colorectal Dis, 15, 1100, 10.1111/codi.12268

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet Lond Engl, 387, 1163, 10.1016/S0140-6736(15)01037-5

Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Patrikidou, 2015, Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome, Urol Oncol Semin Orig Investig, 33, 202e9

Wiegand, 2011, Surgical management of lymph-node-positive prostate cancer: improves symptomatic control, BJU Int, 107, 1238, 10.1111/j.1464-410X.2010.09657.x

Won, 2013, Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer, BJU Int, 112, E250, 10.1111/bju.12169

Sooriakumaran, 2016, A multiinstitutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur Urol, 69, 788, 10.1016/j.eururo.2015.05.023

Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005

James, 2015, Survival with newly diagnosed metastatic prostate cancer in the ‘Docetaxel Era’: Data from 917 Patients in the Control Arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032

Tzelepi, 2011, Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment, J Clin Oncol, 29, 2574, 10.1200/JCO.2010.33.2999

Hong, 2015, Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer, Nat Commun, 6, 6605, 10.1038/ncomms7605

Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347

Kim, 2009, Tumor self-seeding by circulating cancer cells, Cell, 139, 1315, 10.1016/j.cell.2009.11.025

Widmark, 2009, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, Lancet, 373, 301, 10.1016/S0140-6736(08)61815-2

Warde, 2011, Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, Lancet, 378, 2104, 10.1016/S0140-6736(11)61095-7

Mottet, 2012, Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial, Eur Urol, 62, 213, 10.1016/j.eururo.2012.03.053

Verhagen, 2010, Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review, Eur Urol, 58, 261, 10.1016/j.eururo.2010.05.027

Leyh-Bannurah, 2017, Local therapy improves survival in metastatic prostate cancer, Eur Urol, 72, 118, 10.1016/j.eururo.2017.03.020

Rusthoven, 2016, Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer, J Clin Oncol Off J Am Soc Clin Oncol, 34, 2835, 10.1200/JCO.2016.67.4788

Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy versus no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis, J Urol, 194, 378, 10.1016/j.juro.2015.02.084

Fossati, 2015, Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study, Eur Urol, 67, 3, 10.1016/j.eururo.2014.08.056

Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009

Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012

Löppenberg, 2014, The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a National Cancer Data Base analysis, Eur Urol, 72, 14, 10.1016/j.eururo.2016.04.031

Blanchard, 2016, Re: Christopher JD Wallis, Refkin Saskin, Richard Choo et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;70:21-30, Eur Urol, 70, e15, 10.1016/j.eururo.2016.02.040

Giordano, 2008, Limits of observational data in determining outcomes from cancer therapy, Cancer, 112, 2456, 10.1002/cncr.23452

Williams, 2017, Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: the limitations of cancer registry data, Cancer, 123, 1617, 10.1002/cncr.30506

Joensuu, 2016, Multimodal primary treatment of metastatic prostate cancer with androgen deprivation and radiation, Anticancer Res, 36, 6439, 10.21873/anticanres.11242

Kanda, 2016, Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer, Int J Clin Oncol, 21, 764, 10.1007/s10147-016-0947-3

Schick, 2013, Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases, Acta Oncol, 52, 1622, 10.3109/0284186X.2013.764010

Cho, 2016, Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?, PLoS ONE, 11, e0147191, 10.1371/journal.pone.0147191

Halabi, 2016, Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer, J Clin Oncol, 34, 1652, 10.1200/JCO.2015.65.7270

Le Scodan, 2009, Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy, J Clin Oncol l, 27, 1375, 10.1200/JCO.2008.19.5396

Gnerlich, 2007, Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data, Ann Surg Oncol, 14, 2187, 10.1245/s10434-007-9438-0

Badwe, 2015, Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial, Lancet Oncol, 16, 1380, 10.1016/S1470-2045(15)00135-7

Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832, 10.1016/j.juro.2014.09.089